All In Biotech

Drug Trial Radar · NCT07072585

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,708 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,708

Planned (sponsor's estimate)

Start

Aug 28, 2026

Primary completion

Sep 1, 2035

Study completion Sep 1, 2035

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
First posted
Jul 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 365 days, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II/III trial tests the addition of daratumumab to chemotherapy for treating patients with newly-diagnosed T-ALL and T-LL. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with daratumumab may kill more cancer cells.

Conditions

  • Stage II T Lymphoblastic Leukemia/Lymphoma
  • Stage III T Lymphoblastic Leukemia/Lymphoma
  • Stage IV T Lymphoblastic Leukemia/Lymphoma
  • T Acute Lymphoblastic Leukemia
  • T Lymphoblastic Lymphoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Bone ScanProcedure

    Undergo bone scan

  • BortezomibDrug

    Given IV or SC

  • Calaspargase PegolDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT

  • CyclophosphamideDrug

    Given IV

  • CytarabineDrug

    Given IT or IV or SC

  • DaratumumabBiological

    Given IV

  • Daunorubicin HydrochlorideDrug

    Given IV

  • DexamethasoneDrug

    Given PO or IV

  • Doxorubicin HydrochlorideDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • Lumbar PunctureProcedure

    Under lumbar puncture

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Mercaptopurine Oral SuspensionDrug

    Given PO

  • MethotrexateDrug

    Given IT or IV or PO

  • MethylprednisoloneDrug

    Given IV

  • NelarabineDrug

    Given IV

  • PegaspargaseDrug

    Given IV or IM

  • Positron Emission TomographyProcedure

    Undergo PET or PET-CT

  • PrednisoloneDrug

    Given PO or IV

  • PrednisoneDrug

    Given PO or IV

  • Questionnaire AdministrationOther

    Ancillary studies

  • Radiation TherapyRadiation

    Undergo radiation therapy

  • Therapeutic HydrocortisoneDrug

    Given IT

  • ThioguanineDrug

    Given PO

  • Ultrasound ImagingProcedure

    Undergo ultrasound

  • Vincristine SulfateDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS) in patients with newly diagnosed T-cell lymphoblastic leukemia (T-ALL)Time frame: From date of randomization (randomization conducted at the end of induction [EOI]) to date of first event (consolidation failure, interim maintenance failure, relapse, secondary malignant neoplasm [SMN], death from any cause), assessed up to 4 years
  2. EFS in patients with newly diagnosed T-cell lymphoblastic lymphoma (T-LL)Time frame: From date of randomization (randomization conducted at the EOI) to date of first event (consolidation failure, relapse, progressive disease, SMN, death from any cause), assessed up to 4 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.